vs

Side-by-side financial comparison of TRIO-TECH INTERNATIONAL (TRT) and Verastem, Inc. (VSTM). Click either name above to swap in a different company.

TRIO-TECH INTERNATIONAL is the larger business by last-quarter revenue ($15.6M vs $11.2M, roughly 1.4× Verastem, Inc.). TRIO-TECH INTERNATIONAL runs the higher net margin — 0.8% vs -876.3%, a 877.1% gap on every dollar of revenue.

Trio-Tech International is a global provider of semiconductor testing and burn-in solutions, alongside specialized manufacturing services for electronic components. It serves clients across the semiconductor, aerospace, and consumer electronics sectors, with operational footprints spanning North America, Asia, and Europe, delivering custom reliability testing systems and related support services.

Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

TRT vs VSTM — Head-to-Head

Bigger by revenue
TRT
TRT
1.4× larger
TRT
$15.6M
$11.2M
VSTM
Higher net margin
TRT
TRT
877.1% more per $
TRT
0.8%
-876.3%
VSTM

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
TRT
TRT
VSTM
VSTM
Revenue
$15.6M
$11.2M
Net Profit
$126.0K
$-98.5M
Gross Margin
16.0%
Operating Margin
0.6%
-362.2%
Net Margin
0.8%
-876.3%
Revenue YoY
81.6%
Net Profit YoY
-75.1%
-311.1%
EPS (diluted)
$0.01
$-1.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TRT
TRT
VSTM
VSTM
Q4 25
$15.6M
Q3 25
$15.5M
$11.2M
Q2 25
$10.7M
$2.1M
Q1 25
$7.4M
Q4 24
$8.6M
Q3 24
$9.8M
$0
Q2 24
$9.7M
$10.0M
Q1 24
$10.4M
Net Profit
TRT
TRT
VSTM
VSTM
Q4 25
$126.0K
Q3 25
$77.0K
$-98.5M
Q2 25
$183.0K
$-25.9M
Q1 25
$-495.0K
Q4 24
$507.0K
Q3 24
$-236.0K
$-24.0M
Q2 24
$243.0K
$-8.3M
Q1 24
$70.0K
Gross Margin
TRT
TRT
VSTM
VSTM
Q4 25
16.0%
Q3 25
16.7%
Q2 25
24.6%
Q1 25
26.8%
Q4 24
25.7%
Q3 24
23.7%
Q2 24
27.5%
Q1 24
26.0%
Operating Margin
TRT
TRT
VSTM
VSTM
Q4 25
0.6%
Q3 25
0.3%
-362.2%
Q2 25
4.4%
-2047.9%
Q1 25
-4.6%
Q4 24
-0.0%
Q3 24
1.4%
Q2 24
3.7%
-182.8%
Q1 24
0.6%
Net Margin
TRT
TRT
VSTM
VSTM
Q4 25
0.8%
Q3 25
0.5%
-876.3%
Q2 25
1.7%
-1213.6%
Q1 25
-6.7%
Q4 24
5.9%
Q3 24
-2.4%
Q2 24
2.5%
-82.6%
Q1 24
0.7%
EPS (diluted)
TRT
TRT
VSTM
VSTM
Q4 25
$0.01
Q3 25
$0.02
$-1.35
Q2 25
$0.11
$-0.62
Q1 25
$-0.12
Q4 24
$0.06
Q3 24
$-0.06
$-0.60
Q2 24
$0.05
$-0.31
Q1 24
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TRT
TRT
VSTM
VSTM
Cash + ST InvestmentsLiquidity on hand
$16.5M
$137.7M
Total DebtLower is stronger
$581.0K
Stockholders' EquityBook value
$33.5M
$-15.5M
Total Assets
$45.7M
$176.9M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TRT
TRT
VSTM
VSTM
Q4 25
$16.5M
Q3 25
$17.4M
$137.7M
Q2 25
$16.7M
$164.3M
Q1 25
$17.6M
Q4 24
$16.5M
Q3 24
$15.5M
$113.2M
Q2 24
$16.5M
$83.4M
Q1 24
$17.0M
Total Debt
TRT
TRT
VSTM
VSTM
Q4 25
$581.0K
Q3 25
$622.0K
Q2 25
$684.0K
Q1 25
$729.0K
Q4 24
$782.0K
Q3 24
$923.0K
$40.5M
Q2 24
$874.0K
$40.3M
Q1 24
$984.0K
Stockholders' Equity
TRT
TRT
VSTM
VSTM
Q4 25
$33.5M
Q3 25
$34.1M
$-15.5M
Q2 25
$34.0M
$36.1M
Q1 25
$32.3M
Q4 24
$31.8M
Q3 24
$33.1M
$11.1M
Q2 24
$31.3M
$18.9M
Q1 24
$31.2M
Total Assets
TRT
TRT
VSTM
VSTM
Q4 25
$45.7M
Q3 25
$47.4M
$176.9M
Q2 25
$41.1M
$196.3M
Q1 25
$40.0M
Q4 24
$39.8M
Q3 24
$42.9M
$126.4M
Q2 24
$42.5M
$105.7M
Q1 24
$43.1M
Debt / Equity
TRT
TRT
VSTM
VSTM
Q4 25
0.02×
Q3 25
0.02×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.03×
3.66×
Q2 24
0.03×
2.14×
Q1 24
0.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TRT
TRT
VSTM
VSTM
Operating Cash FlowLast quarter
$134.0K
$-36.2M
Free Cash FlowOCF − Capex
$-152.0K
FCF MarginFCF / Revenue
-1.0%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
1.06×
TTM Free Cash FlowTrailing 4 quarters
$137.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TRT
TRT
VSTM
VSTM
Q4 25
$134.0K
Q3 25
$933.0K
$-36.2M
Q2 25
$-664.0K
$-32.7M
Q1 25
$781.0K
Q4 24
$2.1M
Q3 24
$-1.9M
$-23.8M
Q2 24
$199.0K
$-27.6M
Q1 24
$1.2M
Free Cash Flow
TRT
TRT
VSTM
VSTM
Q4 25
$-152.0K
Q3 25
$887.0K
Q2 25
$-1.2M
Q1 25
$623.0K
Q4 24
$1.9M
Q3 24
$-1.9M
Q2 24
$-135.0K
$-27.6M
Q1 24
$1.1M
FCF Margin
TRT
TRT
VSTM
VSTM
Q4 25
-1.0%
Q3 25
5.7%
Q2 25
-11.4%
Q1 25
8.4%
Q4 24
22.4%
Q3 24
-19.7%
Q2 24
-1.4%
-275.8%
Q1 24
10.6%
Capex Intensity
TRT
TRT
VSTM
VSTM
Q4 25
1.8%
Q3 25
0.3%
Q2 25
5.2%
Q1 25
2.1%
Q4 24
2.1%
Q3 24
0.7%
Q2 24
3.4%
0.1%
Q1 24
0.5%
Cash Conversion
TRT
TRT
VSTM
VSTM
Q4 25
1.06×
Q3 25
12.12×
Q2 25
-3.63×
Q1 25
Q4 24
4.16×
Q3 24
Q2 24
0.82×
Q1 24
16.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TRT
TRT

Semiconductor Backend Solutions$12.4M79%
Industrial Electronics$3.3M21%

VSTM
VSTM

Segment breakdown not available.

Related Comparisons